• 55% increase in sales orders compared to same time last year
• USA sleep and Neuroscan business drives 208% sales order growth
• Asia and Europe also see strong sales order growth

Compumedics Ltd, a global medical device company, has announced record sales orders of $32.8m for the first half of the 2025 financial year (H1 FY25), representing a 55% increase compared to the same time last year. The strong performance was driven by exceptional growth in the company's USA business, where sales orders taken for H1 FY25 were 208% higher than the same period last year. The USA sleep and Neuroscan brain analysis business were the key drivers of this growth. The company also saw robust sales order growth in Asia, up 115%, and Europe, up 10%, compared to the same time last year. Compumedics' Somfit product line also contributed to the strong results, with sales orders taken in the USA increasing to approximately $1.0m (USD0.7m), up from zero six months ago. The company is well-positioned to accelerate growth in the second half of FY25 as new sales resources come on board in the USA. While reported revenues for H1 FY25 will be about 13% lower than H1 FY24 due to the timing of a major MEG sale, excluding MEG, revenues are expected to be around 6% higher. EBITDA will be weighted towards the second half due to increased marketing and development costs in the first half, with the sales benefits expected to materialise in the second half.

Company FY25 guidance - sales more than $55m (excluding MEG) and EBITDA above $5m.

The company is well-placed to accelerate growth over H2 FY25 as new sales resources come on board in the USA, building their pipelines and closing deals. The addressable home sleep apnea test (HST) market in the USA represents a significant market opportunity of between $150m (USD100m) and $300m (USD200m) for Compumedics.